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VicrivirocHIV-1 develops resistance to CCR5 antagonists such as Maraviroc (MVC) and Vicriviroc (VVC) both in vitro
and in vivo, with most changes arising in the gp120 V3 region. Both compounds bind to the same hydrophobic
cavity in CCR5 in subtly differentways. Here,we investigatedwhichV3 sequence changes aremost associatedwith
MVC and VVC resistance and how they affect the interaction between gp120 and the CCR5 NT.We found that VVC-
and MVC-selected amino acid changes map to different V3 locations and involve residues that interact with the
CCR5 NT in different ways. Changes in VVC-selected, but notMVC-selected, variants often involve charged residues.
Although the overall V3 charge tends not to change, the introduction or removal of charged residues at speciﬁc
positions affects the local electrostatic potential and could have structural and functional implications. In summary,
VVC and MVC trigger the evolution of distinct HIV-1 resistance patterns in V3.
© 2012 Elsevier Inc. All rights reserved.Introduction
Small molecule CCR5 inhibitors represent a new class of drugs for
treating human immunodeﬁciency virus type 1 (HIV-1) infection.
These molecules bind to a hydrophobic cavity located between the
transmembrane domains of CCR5 and inhibit HIV-1 entry allosterically;
i.e., by inducing conformational changes in CCR5 (Dragic et al., 2000;
Tsamis et al., 2003). For HIV-1 to enter target cells, the gp120 subunit
of theviral envelope glycoprotein (Env) associateswith theCD4 receptor
and the CCR5 coreceptor, inducing a series of conformational changes in
Env that culminate in virus and host cell membrane fusion (Hill et al.,
1997; Kwong et al., 1998; Trkola et al., 1996). Several CCR5-binding
compounds including Maraviroc, Vicriviroc, Aplaviroc, TAK-779, SCH-C
and CMPD 167 antagonize this process and have a strong anti-viral
activity against HIV-1 in vitro (Baba et al., 1999; Dorr et al., 2005;
Strizki et al., 2001, 2005; Veazey et al., 2003; Watson et al., 2005).
Maraviroc (MVC; Pﬁzer) was approved by the FDA in 2007 and is being
used for treating HIV-1-infected people. Vicriviroc (VVC;
Schering-Plough-now Merck) and Aplaviroc (AVC; GlaxoSmithKline)
were tested in clinical trials, but were not pursued because of sub-
optimal efﬁcacy and liver toxicity, respectively.
HIV-1 resistance to CCR5 antagonists can occur both in vitro and in
vivo (Kuhmann et al., 2004; Marozsan et al., 2005; Ogert et al., 2010;
Tsibris et al., 2008). In the most common genetic route to resistance,logy and Immunology, Weill
W-801, New York, NY 10021,
nders).
rights reserved.multiple sequence changes in V3 make the virus more dependent on
the CCR5 N-terminus (NT) (Baba et al., 2007; Berro et al., 2009;
Kuhmann et al., 2004; Nolan et al., 2009; Ogert et al., 2008, 2010;
Tsibris et al., 2008). A much rarer pathway involves changes in the
fusion peptide (FP) of the gp41 protein (Anastassopoulou et al.,
2009). In all cases, the resistant viruses gain the ability to enter cells
via the inhibitor-CCR5 complex while retaining the use of free CCR5
(Pugach et al., 2007).
While VVC andMVC both bind to a similar hydrophobic pocket in the
CCR5 transmembrane domains, they do so in subtly distinctive ways by
interactingwith different amino acids (Labrecque et al., 2011). As a corol-
lary, VVC and MVC (and other class members) may stabilize different
CCR5 conformations, which could inﬂuence the escape pathway taken
by the virus. Although cross-resistance is commonly observed among
the CCR5 inhibitors, there are examples of compound-dependent resis-
tance (Tilton et al., 2010; Westby et al., 2007). Here, we investigate
which sequence changes in V3 aremost associatedwith VVC andMVC re-
sistance, and use molecular models to assess what impact the various
resistance-associated changes have on V3 structure. We found that the
V3 amino acid substitutions in the VVC- and MVC-selected viruses map
to different locations, involve residues with varying electrostatic charges,
and have distinctive effects on how V3 interacts with CCR5 NT.
Results and discussion
MVC and VVC resistance map to different V3 amino acids
We compiled V3 sequences from viruses with proven susceptibility
or resistance to MVC or VVC (Table 1). The sequences were derived
159R. Berro et al. / Virology 427 (2012) 158–165frompatients that failed therapywith the speciﬁed drug, or from escape
viruses selected in vitro under the selection pressure of one of the
compounds (Jakobsen et al., 2011; Kuhmann et al., 2004; Lewis et al.,
2010; McNicholas et al., 2010, 2011; Ogert et al., 2008, 2009, 2010;
Pﬁzer, 2007; Putcharoen et al., 2011; Tilton et al., 2010; Tsibris et al.,
2008; Westby et al., 2007; Yuan et al., 2011). In total, sequences from
14 VVC-selected and 18 MVC-selected clones were compared to the
inhibitor-sensitive clones from which they were derived (Table 1).
When multiple V3 sequences were available from the resistant viruses,
we used only the one associated with the lowest maximum percent
inhibition (MPI) value (i.e., from the most resistant clone). In cases
where the sequence appears to indicate that two different resistant
variants were present in the viral quasispecies, both were analyzed
independently. In the original studies, four of the 14VVC-selected viruses
were tested for MVC sensitivity and found to be cross-resistant, while
none of the three tested MVC-selected viruses was cross-resistant to
VVC (Table 1). However, even when cross-resistance to MVC was
demonstrated, the viruses were generally more resistant to the selecting
compound, VVC, as indicated by lowerMPI values (Kuhmann et al., 2004;
Putcharoen et al., 2011; Tsibris et al., 2008).Table 1




































a All sequences correspond to individual Env clones except those from the MOTIVATE tri
clones from the same patient.
b Residues highlighted in red indicate substitutions that have been conﬁrmed to cause re
c In all cases, inhibitor susceptibility was determined in the U87-CD4-CCR5 cell line excep
d CR=cross-resistance; Y: yes, N: No; NT: not tested. e Clade not identiﬁed; in Yuan e
mutations introduced at 10 different residues (Yusa et al., 2005).
f The selecting agent was AD101, a pre-clinical precursor of VVC with similar structural
g Negative MPI values indicate an enhanced replication in the presence of the selecting dWe ﬁrst compared the location of V3 amino acid substitutions
between VVC- and MVC-selected clones, taking note only of changes
that occurred more than once at the same location in each sequence
dataset (Fig. 1A). MVC-associated changes arose only in 7 positions
located in the V3 tip and stem regions, whereas VVC-associated
changes were more widely distributed, involving 15 positions
scattered throughout the tip, stem and base of V3 (Fig. 1A).
Some resistance-associated changes were predominant for one of
the selecting compounds. The most frequent (6/18 sequences) MVC-
associated substitution occurred at amino acid Ile-322a, which was
always substituted with Val (the amino acid designated 322a is not
present in HXB2 but is located between residues 322 and 323 of
that virus). In contrast, changes to this residue never arose under
the selection pressure of VVC (0/14 sequences, p=0.020, one-tailed
Fisher's exact test, for the comparison). Conversely, an Arg substitution
at Lys-305 was frequently associated with VVC selection (in 6/14
sequences) but was seen with MVC only once (1/18 sequences,
p=0.017, one-tailed Fisher's exact test, for the comparison). A
substitution at Gly-321 arose 4 times under VVC selection, in 3 cases
involving a change to Glu, and was always accompanied by theMPIc CR to MVCd  Reference
Putcharoen et al. 2011 
McNicholas et al. 2010 
Ogert et al. 2008, 2009 
Tsibris et al. 2008 
Kuhmann et al. 2004f  
McNicholas et al. 2011 
al of MVC (Lewis et al. 2010; Pﬁzer, 2007), which represent the consensus of multiple
sistance, and in blue, substitutions that have not been veriﬁed.
t for Jakobsen et al., 2011 and Tilton et al., 2010 where NP2-CD4-CCR5 cells were used.
t al., 2011, the resistant virus was selected from a V3 loop library virus, with random
properties.
rug as compared to no drug.
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160 R. Berro et al. / Virology 427 (2012) 158–165TK305R change. Comparing how frequently each V3 residue was chan-
ged in the VVC- and MVC-escape virus datasets, we found that only
substitutions at I322a (for MVC escapes), or K305 and G/D321 (for
VVC escapes) were statistically different between the two selecting
compounds (pb0.05, one-tailed Fisher's exact test, Table 2). Changes at
these residues could, therefore, be signatures for MVC vs. VVC resistance.
The amino acids present at V3 positions 308 and 322 vary both
between and within clades (Table 2). Substitutions at these two
locations frequently arose under the selection pressure of each
compound (Fig. 1A). For MVC-selected clones, the residue introduced
at position 322 was always Asp, which is a common polymorphism at
this site in subtype B viruses (Table 2). However, no speciﬁc substitu-
tion pattern could be discerned at position 322 of VVC-selectedviruses. Residue-308 is naturally highly polymorphic in clade B
(Table 2); changes here were commonly seen in response to both VVC
and MVC selection, but there was no evidence for the introduction of
any speciﬁc amino acid.
To determinewhether resistance-associated V3 changes occur at rela-
tively conserved or polymorphic sites, we looked at the natural sequence
variation pattern at the same sites (Table 2). The dataset was based on a
study exploring the variation ofmore than 350 V3 sequences fromviruses
of both clades B and C (Patel et al., 2008). We found that none of the
MVC- or VVC-associated substitutions arose at the more highly
conserved V3 residues, but rather at positions where various amino
acids are naturally tolerated (Table 2). Thus, the selection pressure of
both CCR5 inhibitors may favor the expansion of pre-existing minor
Fig. 1. MVC and VVC resistance map to different amino acids. A. Amino acid substitutions identiﬁed in all VVC- or MVC-selected viruses were mapped to the 35 amino acids of V3.
The amino acid positions are based on the CC1/85 sequence (Kuhmann et al., 2004). The numbering on top of the bars and everywhere in the main text corresponds to the HXB2
reference strain. The amino acid designated 322a is not present in HXB2 but is located between residues 322 and 323 of that virus. B. Surface rendering of V3 showing the sites of VVC-
associated (upper panel) and MVC-associated substitutions (lower panel) in red. The intensity of red matches the frequency of substitutions (see panel A). The docked structure of the
CCR5 NT (Huang et al., 2007) is rendered in yellow. C. Detail of the hydrophobic interactions of Ile-322a. The hydrophobic interactions that Ile-322a can make with Tyr-10, Asp-11
and Tyr-14 are indicated by yellow dotted lines.
161R. Berro et al. / Virology 427 (2012) 158–165variants with a degree of natural resistance. Indeed, that process has
been described previously (Kuhmann et al., 2004; Roche et al., 2011).
Alternatively, these substitutionsmay also arise during therapy de novo.
Structural implications of the VVC-associated resistance changes
Wemapped the substitutions that arose in VVC-escape variants on
the structure of a model of the V3 region in complex with a fragmentof the CCR5 NT that includes residues 7–15 (Fig. 1B) (Huang et al.,
2007). The model includes Asp-11 and the sulfated tyrosines at
positions 10 and 14, the three key CCR5 residues interacting with
V3 (Berro et al., 2009; Farzan et al., 1999). The model predicts that
the most commonly substituted amino acids in the V3 regions of
VVC-selected viruses do not directly contact CCR5 residues Tyr-
10, Asp-11 and Tyr-14. Residues 321 and 322 are often altered in
the V3 regions of VVC-resistant viruses; they are predicted to
Table 2
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10/ 305 K K/R (6) K(83%), R(16%) K(73%), R(11%), E (8%), Q (4%), T
(3%)
0.017
11/ 306 S S/P (2), G/P (1) S(78%), G(21%) S(96%), G(3%) 0.21
12/ 307 I 0.69
13/ 308 H,R N/D (2), H/Y (1),
H/P (1), H/D (1)
P/H (2), N/H (2),
P/S (1)
H(63%), P(16%), N(11%),
S (4%), T (3%)
R(94%), G(5%), K (b1%), T (b 1%) 0.46




16/ 313 P P/A (2) P(88%), W(5%), L(2%) P(100%) 0.31
17/ 314 G G/A (2), G/W (1) G(98%), R(b1%), E (b1%),
W (b1%), V (b1%)
G(100%) 0.073
18/ 315 R,Q R/K (1), R/E (1),
Q/E (1), R/Q (1)
R(73%), K(11%), S(6%),
Q(6%), G(3%)
Q(99%), R (b1%) 0.099
19/ 316 A,T A/V (2) T/A (1), A/S (1),
A/T (2), A DEL (1)
A(90%), T(6%), V(2%) T(68%), A(28%), V(2%) 0.32
20/ 317 F I/F (1), L/F (1) F/W (1), I/F (2),




21/ 318 Y Y/W (1), Y/I (1),
F/I (2)
Y(90%), F(6%), H(3%) Y(88%), F(11%) 0.099
22/ 319 T,A K/T (1), G/A (1) T/A (2), A/T (1) T(46%), A (53%) A(98%), T(1%) 0.62
23/ 320 T T/R(1), T/P(1) T (>95%) T (>95%) 0.4
24/ 321 G G/E (3), G/A (1),
D/N (1)
G(97%), E(2%) G(79%), N(13%), D(3%), K(2%) 0.043
25/ 322 E,D E/D (2), D/G (2),
R/G (1)




D(54%), E(17%), G(14%), A(7%),
N(3%)
0.33






32/ 328 Q Q/R (1), E/K (1) Q (88%), K (7%), R (4%),
E (1%)
Q (83%), K (6%), E (5%), R (3%) 0.4
33/ 329 A
34/ 330 H H/Y (2), Y/H (1) H (87%), Y (12%/) H (83%), Y (15%) 0.07
35/ 331 C
a Residues conserved in >98% of clade B and C sequences are highlighted in bold.
b Only substitutions that occur more than once at the same V3 position within the same dataset are displayed; all sequences in Table 1 were included in the analysis.
c Differences in substitution frequency of pb0.05 based on a Fisher's exact test were considered statistically signiﬁcant and are shown in italics.
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positions may change the gp120-CCR5 interaction is discussed
below. The other V3 residues that are often substituted in VVC-
resistant viruses are not thought to contact the CCR5 NT; several are
located near the V3 tip and may modulate the interaction with ECL2,
directly or otherwise.
Structural implications of the MVC-associated resistance changes
The most commonly altered residue in MVC-selected viruses, Ile-
322a (found 6 times), was invariant when VVC was the selecting drug
(p=0.020, one-tailed Fisher's exact test, for the comparison). This res-
idue contacts all three key residues in the CCR5 NT that are predicted to
interact with V3, namely Asp-11, Tyr-10 and Tyr-14. The hydrophobic
side chain of Ile-322a intercalates between all three CCR5 residues,
making hydrophobic contacts with the aromatic rings of both Tyr resi-
dues and also with the backbone of Asp-11 (Fig. 1C).When Val replacesIle at position 322a, which frequently occurs under MVC selection, the
loss of the methyl group is likely to alter the hydrophobic packing of
these interactions and thereby modulate how V3 interacts with the
CCR5 NT. A model of a MVC-resistant V3 predicted that the I322aV
change disrupted a β-sheet in the stem, creating amore disordered sec-
ondary structure in this region, and that the introduced Val residue
would occupy less space than the original Ile, thus reducing the inter-
face areas between V3 and the CCR5 NT (Roche et al., 2011).
Substitutions at the neighboring residue 322, which contacts Ser-7
and Asp-8 of the CCR5 NT, are involved in both VVC- and MVC-
resistance, but different amino acids are introduced in each case.
Under VVC selection, the change is usually from a charged amino acid
(most commonly Asp) to another charged or neutral one, while with
MVC there appears to be a selective preference for Asp. It is unclear
how these changes affect V3-CCR5 interactions (but see below). Other
frequently changed residues located more towards the tip of V3 do
not contact the CCR5 NT directly.
Fig. 2. VVC-resistance, but not MVC-resistance involves a redistribution of V3 charge. A. MVC- and VVC-associated substitutions involving a charged residue are displayed as the
total number of charged changes per V3 pair. ***, pb0.0001 (one-tailed Mann–Whitney U test). B. A comparison of the net charge of the V3 sequences from MVC- or VVC-
selected viruses. N.S., non-signiﬁcant (p>0.05, one-tailed Mann–Whitney U test). C. Electrostatic surface potential of a representative VVC-sensitive/resistant V3 pair (Tsibris et
al., 2008). Sensitive virus, upper panels; resistant virus, lower panels. The right panels are rotated to allow CCR5 residues Tyr-14 and Asp-11 to be viewed.
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charge
TheV3 region of CCR5-using viruses has a net positive charge (median
of 3) (Clevestig et al., 2006), and how V3 interacts with CCR5 is strongly
inﬂuenced by its electrostatic potential (Cormier et al., 2001). We
therefore studied the electrostatic properties of the V3 residues that
change in response to MVC or VVC selection. Our emphasis was on
neutral-to-charged residue changes, and vice versa, and substitutions
that introduced a different charged residue at the same position (Fig. 2A).
Viruses selected by VVC contained several V3 substitutions to or
from a charged residue (median=2), while their MVC-selected
counterparts did not (median=0) (Fig. 2A). The difference was
highly signiﬁcant (pb0.0001, one-tailed Mann–Whitney U test),
even when we normalized to the total number of changes
(pb0.0001). The latter number (i.e. total number of substitutions
per V3 sequence) was slightly higher for VVC because the
sequences were usually derived from a later time point during
therapy (data not shown). The net charge of MVC-selected V3regions did not change (median=0), but for VVC there was a
non-signiﬁcant trend towards a decrease in positive charge (medi-
an=−1) (Fig. 2B).
To see how the charge changes that are selected duringVVC-therapy
might modulate how V3 interacts with the CCR5 NT, we studied the
electrostatic surface potential of one VVC-sensitive/resistant V3 pair
that contains three frequently occurring changes: K305R (observed 6
times, overall), S/G306P (3 times) and G321E (3 times) (Tsibris et al.,
2008). The G321E change was always present together with K305R,
suggesting an evolutionary linkage. That this combination was never
found in MVC-selected viruses implies speciﬁcity for VVC-resistance.
The parental, VVC-sensitive sequence forms a large, positive surface
containing a cavity that accommodates the sulfated Tyr-14 residue of
CCR5, while the sulfated Tyr-10 residue binds at the edge of the positive
surface (Fig.2C, upper panels). The VVC-selected V3 changes did not
affect the electrostatic surface potential of the binding sites for Tyr-10
and Tyr-14 (Fig.2C, lower panels). However, positive charge was lost
from regions near position 305 located towards the middle of V3. The
cause was not the K305R substitution, but rather that the glutamic
164 R. Berro et al. / Virology 427 (2012) 158–165acid introduced by the accompanying G321E change neutralizes the
positive charge of Arg-305 via formation of a salt bridge. We have
previously suggested that the K305R plus G321E combination may
contribute to V3 stability by favoring a β-sheet structure through
formation of an inter-strand salt bridge (Berro et al., 2009). Overall, it
seems possible that this pair of substitutions affects how V3 interacts
with Asp-11 on the CCR5 NT, both by stabilizing a particular β-sheet
conformation and by changing the electrostatic surface potential.
Whatever the underlying mechanism, the outcome may be a reduced
or lost interaction between V3-residue 305 and Asp-11 on CCR5.
In general, to acquire the ability to bind the inhibitor-CCR5
complex and become resistant, gp120 may need to sacriﬁce some
contacts that are normally involved in its interaction with free
CCR5. That loss may have adverse consequences for the efﬁciency of
CCR5 binding and hence virus entry in the absence of the selecting
compound, i.e., via free CCR5. Thus, some resistant viruses selected
during VVC-therapy in vivo have delayed entry kinetics in the absence
of VVC, indicative of a ﬁtness loss, but the addition of the inhibitor
restored the rate of entry to a level comparable to wild type viruses
(Putcharoen et al., 2011; Tsibris et al., 2008). A similar loss of ﬁtness
that was also reversed upon addition of the inhibitor was observed
in viruses selected for VVC-resistance in vitro (Anastassopoulou et
al., 2007). When the inhibitor is present, the weakening of the inter-
action between V3 and the CCR5 NT may be compensated for by the
acquisition of additional binding sites involving the NT or other
regions of the inhibitor-CCR5 complex. Further evidence that the
resistance-associated V3 changes affect the overall geometry of the
Env complex is that resistant viruses become more sensitive to neu-
tralizing antibodies against V3 (Berro et al., 2009; Laakso et al.,
2007; Nolan et al., 2009).
Conclusion
The MVC- and VVC-selected sequence changes map to different
amino acids in V3 but in both cases they generally arise at naturally
polymorphic sites. The two sets of changes are each likely to
modulate how V3 interacts with the CCR5 NT, but in different ways.
Why do MVC and VVC drive different patterns of V3 changes? The
two compounds presumably alter the overall conformation of CCR5
in subtly distinctive ways, via interactions with different residues in
the transmembrane cavity where they each bind, as judged by the
ability of these compounds to affect the binding of various
conformation-dependent monoclonal antibodies to CCR5 (Tilton
et al., 2010). In both cases, the geometry of the CCR5 NT and ECL2
regions is modiﬁed so as to alter the multi-point binding site that
HIV-1 normally recognizes. The virus counters by introducing V3
sequence changes that allow it to still interact with the CCR5 NT,
but in a different way. However, exactly what V3 changes allow this
interaction must depend on the precise orientation of the NT on the
inhibitor-CCR5 complex, which must differ, to at least some extent,
between MVC and VVC. Understanding the details would require
detailed structural information on CCR5 (free and ligated by each
inhibitor) and the native Env trimer, which is presently unavailable.
That kind of structural information would also help us understand
why VVC-selected variants tend to be cross-resistant to MVC, where-
as MVC-selected viruses sometimes remain sensitive to VVC and
other similar inhibitors.
Finally, this is the ﬁrst comprehensive study comparing the
pattern of sequence changes induced by VVC and MVC resistance.
Although the total number of sequences analyzed was limited by
the extent of published data, it is clear that the two drugs drive
different patterns of V3 changes. Because the V3 is highly variable it
lends itself to a high level of baseline variability. Therefore, the
power of our analysis could be enhanced in the future by a larger
data set and a clade-speciﬁc sequence analysis. Our conclusion that
different small molecule CCR5 inhibitors drive different resistancemechanisms should be clinically relevant. Knowing that the various
drugs might lead to different mechanisms of resistance should assist
the design and development of the next generation CCR5 antagonists
and anticipate the viral escape pathways.
Materials and methods
Statistical analysis
The V3 sequence charge redistribution was analyzed using the
Mann–Whitney U test in GraphPad Prism (GraphPad, San Diego,
CA). The number of changes involving charge per V3 sequence was
determined for each selecting compound and then compared
between the two datasets. Changes to or from a charged residue
were counted.
To compare whether substitutions at certain V3 residues were
associated with VVC or MVC-selection pressure, we calculated the
frequency of substitution of each V3 residue in each dataset (VVC
vs. MVC). Thus, we divided the number of substitutions at a certain
position by the total number of sequences in each dataset. We then
compared the substitution frequency between the two datasets to
determine whether changes at certain V3 positions were associated
with resistance to one inhibitor vs. the other by performing a Fisher's
exact test. p-Valuesb0.05 were considered statistically signiﬁcant,
and hence indicative of V3 positions that are more likely to be
changed as a response to one inhibitor vs. the other.
Structural analysis
The structure of a V3-containing gp120 in complexwith CD4 and the
sulfated 412 d antibody (Protein Databank (pdb) accession code:
2QAD) was used for the structural analyses, in combination with a
model of a docked structure of the CCR5 NT (Huang et al., 2007);
http://www.niaid.nih.gov/labsandresources/labs/aboutlabs/vrc/structu
ralbiologylaboratory/Pages/kwong.aspx). Substitutions andelectrostatic
surface potentials were generated using Pymol (www.pymol.org) and
ﬁgures were prepared using Pymol.
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